Merck Partners with Versant Ventures to Launch Saturnus Bio
Merck has partnered with Versant Ventures to establish Saturnus Bio, advancing precision medicine through gene modulation technologies for rare genetic cardiomyopathies.
Cardiovascular Drug Development | 25/06/2026 | By News Bureau
Atrium Therapeutics receives a USD 15 million milestone payment from Bristol Myers Squibb under a global collaboration to develop innovative RNA-based therapies for cardiovascular diseases.
Cardiovascular Drug Development | 24/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy